170 related articles for article (PubMed ID: 23818939)
1. Filgrastim XM02 (Tevagrastim®) after autologous stem cell transplantation compared to lenograstim: favourable cost-efficacy analysis.
Gardellini A; Gigli F; Babic A; Andreola G; Radice D; Sammassimo S; Martinelli G; Laszlo D
Ecancermedicalscience; 2013; 7():327. PubMed ID: 23818939
[TBL] [Abstract][Full Text] [Related]
2. Monocentric Analysis of the Effectiveness and Financial Consequences of the Use of Lenograstim versus Filgrastim for Mobilization of Peripheral Blood Progenitor Cells in Patients with Lymphoma and Myeloma Receiving Chemotherapy and Autologous Stem Cell Transplantation.
Restelli U; Croce D; Bonizzoni E; Marzanatti M; Andreini A; Sorio M; Tecchio C; Barison E; Benedetti F
J Blood Med; 2020; 11():123-130. PubMed ID: 32308515
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a biosimilar granulocyte colony-stimulating factor (filgrastim XM02) for peripheral blood stem cell mobilization and transplantation: a single center experience in Japan.
Yoshimura H; Hotta M; Nakanishi T; Fujita S; Nakaya A; Satake A; Ito T; Ishii K; Nomura S
J Blood Med; 2017; 8():5-12. PubMed ID: 28182150
[TBL] [Abstract][Full Text] [Related]
4. Biosimilar Filgrastim (Tevagrastim, XMO2) for Allogeneic Hematopoietic Stem Cell Mobilization and Transplantation in Patients with Acute Myelogenous Leukemia/Myelodysplastic Syndromes.
Danylesko I; Sareli R; Bloom-Varda N; Yerushalmi R; Shem-Tov N; Shimoni A; Nagler A
Biol Blood Marrow Transplant; 2016 Feb; 22(2):277-283. PubMed ID: 26343949
[TBL] [Abstract][Full Text] [Related]
5. XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy.
Engert A; Griskevicius L; Zyuzgin Y; Lubenau H; del Giglio A
Leuk Lymphoma; 2009 Mar; 50(3):374-9. PubMed ID: 19347726
[TBL] [Abstract][Full Text] [Related]
6. Use of biosimilar filgrastim compared with lenograstim in autologous haematopoietic stem-cell transplant and in sibling allogeneic transplant.
Uddin S; Russell P; Farrell M; Davy B; Taylor J; Agrawal SG
Ther Adv Hematol; 2015 Apr; 6(2):53-60. PubMed ID: 25830013
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of biosimilar Peg-filgrastim after autologous stem cell transplant in myeloma and lymphoma patients: a comparative study with biosimilar Filgrastim, Lenograstim, and originator Peg-filgrastim.
Marchesi F; Terrenato I; Papa E; Tomassi M; Falcucci P; Gumenyuk S; Palombi F; Pisani F; Renzi D; Romano A; Spadea A; Regazzo G; Rizzo MG; De Rienzo M; Ripellino C; Sgromo S; Viggiani C; Ponte E; Kayal R; Cordone I; Foddai ML; Mengarelli A
Ann Hematol; 2024 Mar; 103(3):947-956. PubMed ID: 38189833
[TBL] [Abstract][Full Text] [Related]
8. Biosimilar Filgrastim in Autologous Peripheral Blood Hematopoietic Stem Cell Mobilization and Post-Transplant Hematologic Recovery.
Marchesi F; Mengarelli A
Curr Med Chem; 2016; 23(21):2217-29. PubMed ID: 27183986
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of granulocyte colony-stimulating factor biosimilars in engraftment after autologous stem cell transplantation for haematological malignancies: a 4-year, single institute experience with different conditioning regimens.
Bassi S; Stroppa EM; Moroni CF; Arbasi MC; Trabacchi E; Di Franco A; Lazzaro A; Bernuzzi P; Moretto M; Arcari A; Bosi C; Riva A; Cavanna L; Vallisa D
Blood Transfus; 2015 Jul; 13(3):478-83. PubMed ID: 25761321
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the potency of glycosylated and nonglycosylated recombinant human granulocyte colony-stimulating factors in neutropenic and nonneutropenic CD rats.
Nohynek GJ; Plard JP; Wells MY; Zerial A; Roquet F
Cancer Chemother Pharmacol; 1997; 39(3):259-66. PubMed ID: 8996530
[TBL] [Abstract][Full Text] [Related]
11. XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy.
Gatzemeier U; Ciuleanu T; Dediu M; Ganea-Motan E; Lubenau H; Del Giglio A
J Thorac Oncol; 2009 Jun; 4(6):736-40. PubMed ID: 19404210
[TBL] [Abstract][Full Text] [Related]
12. Biosimilar G-CSF versus filgrastim and lenograstim in healthy unrelated volunteer hematopoietic stem cell donors.
Farhan R; Urbanowska E; Zborowska H; Król M; Król M; Torosian T; Piotrowska I; Bogusz K; Skwierawska K; Wiktor-Jędrzejczak W; Snarski E
Ann Hematol; 2017 Oct; 96(10):1735-1739. PubMed ID: 28801752
[TBL] [Abstract][Full Text] [Related]
13. Comparison of lenograstim and filgrastim: effects on blood cell recovery after high-dose chemotherapy and autologous peripheral blood stem cell transplantation.
Hüttmann A; Schirsafi K; Seeber S; Bojko P
J Cancer Res Clin Oncol; 2005 Mar; 131(3):152-6. PubMed ID: 15583936
[TBL] [Abstract][Full Text] [Related]
14. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
[TBL] [Abstract][Full Text] [Related]
15. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey.
Sivgin S; Karakus E; Kaynar L; Kurnaz F; Pala C; Keklik M; Zararsiz G; Solmaz M; Eser B; Cetin M; Unal A
Transfus Apher Sci; 2013 Jun; 48(3):315-20. PubMed ID: 23611684
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients.
Martino M; Recchia AG; Moscato T; Fedele R; Neri S; Gentile M; Alati C; Vincelli ID; Piro E; Penna G; Musolino C; Ronco F; Molica S; Morabito F
Cytotherapy; 2015 Oct; 17(10):1485-93. PubMed ID: 26188967
[TBL] [Abstract][Full Text] [Related]
17. Biosimilar granulocyte colony-stimulating factor is effective in reducing the duration of neutropenia after autologous peripheral blood stem cell transplantation.
Cioch M; Jawniak D; Kotwica K; Wach M; Mańko J; Gorący A; Klimek P; Mazurkiewicz E; Jarosz P; Hus M
Transplant Proc; 2014 Oct; 46(8):2882-4. PubMed ID: 25380941
[TBL] [Abstract][Full Text] [Related]
18. Peripheral blood stem cell mobilization and engraftment after autologous stem cell transplantation with biosimilar rhG-CSF.
Reményi P; Gopcsa L; Marton I; Réti M; Mikala G; Pető M; Barta A; Bátai A; Farkas Z; Borbényi Z; Csukly Z; Bodó I; Fábián J; Király A; Lengyel L; Piukovics K; Torbágyi E; Masszi T
Adv Ther; 2014 Apr; 31(4):451-60. PubMed ID: 24687301
[TBL] [Abstract][Full Text] [Related]
19. Lenograstim versus filgrastim in mobilization before autologous hematopoietic stem cell transplantation in patients with multiple myeloma and lymphoma - Single center experience.
Sarıcı A; Erkurt MA; Bahçecioğlu ÖF; Biçim S; Berber İ; Gök S; Kaya E; Özgül M; Kuku İ
Transfus Apher Sci; 2021 Aug; 60(4):103127. PubMed ID: 33863669
[TBL] [Abstract][Full Text] [Related]
20. Mobilization of PBSC for allogeneic transplantation by the use of the G-CSF biosimilar XM02 in healthy donors.
Schmitt M; Xu X; Hilgendorf I; Schneider C; Borchert K; Gläser D; Freund M; Schmitt A
Bone Marrow Transplant; 2013 Jul; 48(7):922-5. PubMed ID: 23318540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
